eBook | Improved Indirect Power Control (IDPC) of Wind Energy Conversion Systems (WECS)

 

animalCells.jpg

BY

FAYSSAL AMRANE, AZEDDINE CHAIBA

 

During the past decade, the installed wind power capacity in the world has been increasing more than 30%. Wind energy conversion system (WECSs) based on the doubly-fed induction generator (DFIG) dominated the wind power generations due to the outstanding advantages, including small converters rating around 30% of the generator rating, lower converter cost.

Due to the non-linearity of wind system, the DFIG power control presents a big challenge especially under wind-speed variation and parameter’s sensibility.

To overcome these major problems; an improved IDPC (Indirect Power Control); based on PID “Proportional-Integral-Derivative” controller, was proposed instead the conventional one (based on PI), in order to enhance the wind-system performances in terms; power error, tracking power and overshoot. Unfortunately using robustness tests (based on severe DFIG’s parameters changement); the wind-system offers non-satisfactory simulation results which were illustrated by the very bad power tracking and very big overshoot (> 50%).

In this context; adaptive, robust & intelligent controllers were proposed to control direct & quadrature currents (Ird & Irq) under MPPT (Maximum Power Point Tracking) strategy to main the unity power factor (PF≈1) by keeping the reactive power at zero level. In this case, the new IDPC based on intelligent controllers offered an excellent wind-system performance especially using robustness tests, which offered a big improvement especially using Type-1 Fuzzy Logic Controller (T1-FLC), Type-2 Fuzzy Logic Control (T2-FLC; is the New class of fuzzy logic) & Neuro-Fuzzy Logic (NFC).

In this sense, I think that this edited book is an important contribution to help students already in mastery of the basis of power electronic circuits and control systems theory to achieve these pedagogical goals. The proposed book describes with easy manner the modeling & control of Wind-turbine DFIG in order to control the stator powers using different topologies of robust, adaptive and intelligent controllers.

The book present numerous intelligent control techniques that help in the control design of the DFIG wind-system (WT).

The textbook “Improved Indirect Power Control (IDPC) of Wind Energy Conversion Systems (WECS)” proposes a collection of concepts, organized in a synergic manner such that to ease comprehension of the WT control design.

The book’s contribution goes towards completing the already existing literature by offering a useful integration of control techniques, worthy to be read, understood and employed in the various WT applications. Please enjoy reading this book. Read out the full version here.

Press Release | Bentham Science journals improve impact factor ratings in 2019

 

The latest edition of Journal Citation Reports® 2019 has been published recently, and according to the report, Bentham Science Publishers (BSP) journals have significantly improved their Impact Factors. Current Neuropharmacology is leading the list again with the highest impact factor (IF: 4.568) among all the journals. In total, 40 BSP journals have received Impact Factor ratings this year. The latest results in the JCR 2019 reflect the high quality of research published by Bentham Science.

Journal Citation Reports (JCR) is an annual publication by Clarivate Analytics. JCR has been integrated with the Web of Science and is accessible from the Web of Science-Core Collections. Its purpose is to offer a systematic means to critically evaluate the world’s leading journals, with quantifiable, statistical information based on citation data.

Bentham Science publishes over 100 print & online scholarly subscription journals and books. Learn more about Bentham Science here: http://www.benthamscience.com

 

Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-bsl062019.php

Become Bentham Ambassador | Venoms and Toxins

The Journal Venoms and Toxins is interested in appointing active Bentham Ambassador on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Ambassador, please send us your CV. If, however, the scope of the journal is not directly related to your field, you may, if you wish, also recommend some young researchers as “Associate Bentham Ambassadors” to magnify this effort, and, if possible, send their CV.

Mention in the subject line, the field of interest and send your CV at: hermain@benthamscience.net and CC: faizan@benthamscience.net

Become-an-Ambassador.jpg

Benefits available to Bentham Ambassadors

Bentham has developed a comprehensive system of rewards and benefits for Bentham Ambassadors some of which are mentioned below:

1.  As a Bentham Ambassador, you would have the possibility of having your article(s) published as Open Access in any Bentham Science journal of your choice (once you have earned enough points to avail this facility). For a listing of journals please refer to http://benthamscience.com/

2.  You would have the possibility to get complementary online access to any three selected Bentham eBooks (http://ebooks.benthamscience.com/) for one calendar year.

3.  The most active Ambassadors can avail discounts on conferences supported by Bentham in respect of registration fee.

4.  You will also receive a souvenir (such as tie, collar logo, or pure leather wallet bearing the Bentham logo).

5.  Your name and affiliation will be mentioned on a dedicated Bentham Ambassadors web page which will help you in your promotional activities as your position will be visible for all to see.

6.  As a Bentham Ambassador you will also be entitled to avail a 25% discount on all Bentham Science content as well as various other Bentham services like Quick Track, Open Access plus, e-prints/reprints, color figures, figures enhancement services, etc.

 

http://www.benthamambassadors.com/

Editors Choice Article | EH-42: A Novel Small Molecule Induces Apoptosis and Inhibits Migration and Invasion of Human Hepatoma Cells through Suppressing STAT3 Signaling Pathway

Journal Name: Current Cancer Drug Targets

Author(s): Qi-Zhe Gong, Di Xiao, Gui-Yi Gong, Jian Xu, Xiao-Dong Wen*, Feng Feng*, Wei Qu*.

 

 

Background: Since signal transducer and activator of transcription 3 (STAT3) is aberrantly activated in hepatocellular carcinoma (HCC) and plays a key role in this tumor progression. Inhibition of the STAT3 signaling pathway has been considered as an effective therapeutic strategy for suppressing HCC development.

Objective: In this study, we investigated the anti-cancer effects of EH-42 on HCC cells and tried to explain the underlying mechanism.

Methods: MTT assay, colon formation assay and AnnexinV-FITC/PI double-staining assay were performed to assess the effects of EH-42 on cell growth and survival. Wound healing assay and transwell invasion assay were performed to assess the effects of EH-42 on cell migration and invasion. Western blotting assay was performed to analyze the effects of EH-42 on relative proteins.

Results: According to the MTT assay, colon formation assay and AnnexinV-FITC/PI doublestaining assay, EH-42 could suppress the growth and induce apoptosis of HCC cells in a dosedependent manner. Further western blotting assay showed that the inhibitory effects of EH-42 on cell growth and survival were caused by activating caspase 3/9, suppressing the phospho-STAT3 (Tyr 705) and downregulating anti-apoptotic proteins like Bcl-2/Bcl-xL. Moreover, migration and invasion abilities of HCC cells were also inhibited by EH-42 in the wound healing assay and transwell invasion assay. The potential mechanism was that EH-42 could inhibit HCC metastasis via reversing epithelial-mesenchymal transition and downregulating the secretion of MMPs.

Conclusion: Taken together, these findings suggested that EH-42 could be a potential therapeutic agent for HCC treatment. To read out more, please visit: http://www.eurekaselect.com/168569/article

Publish your medical research for free | Venoms and Toxins

Publish your Medical Research for FREE in our journal “VENOMS AND TOXINS”

All articles published in the first year would be free!

 

To submit your paper, email at: hermain@benthamscience.net and CC: faizan@benthamscience.net

Venoms and Toxins.jpg

AIMS & SCOPE

Venoms and Toxins publishes up-to-date review articles, research articles, thematic issues, short communications, and case reports covering all aspects of toxins, venomous animals (e.g. scorpions, snakes, sea anemones, cone snails, worms, wasps and frogs) and their derivative products.

The journal is devoted to the many aspects of marine and non-marine toxins/molecules (and derivatives thereof) from animal venoms, including their structural characteristics, structure-function relationship, pharmacological and immunological properties, molecular engineering/drug design, biotechnological potential, and therapeutic value. The journal also covers all aspects of other types of toxins (including toxic substances of non-protein/peptide origin), such as plant/algae, viral and bacterial toxins.

Bentham Science Free Trial in Annamalai University | Free Trial ends on 29th September, 2019

 

Wordpress

 

It is our pleasure to inform you that Bentham Science Publishers has activated a 3 month trial subscription for Annamalai University. The trial subscription covers access to Bentham Science journal content.

Bentham Science uses the platform; Eurekaselect (our proprietary platform) for offering journal trials. The trial has been activated on Eureka

Members of your library can view all Bentham Science journal issues (2000-2019) in full text, via the following URL: www.eurekaselect.com

Online Trial Access Procedure:

To access the free trial offer, you do not need to insert a user ID or a password. Instead you can access the following URL by logging through the library’s registered IP Addresses in your browser:

Eureka Select: http://www.eurekaselect.com/bypublication

Free Trial Announcement Among The Users Of Your Library/Institution

We will appreciate it if you could announce the availability of this free trial to all the members of your library/institution. By alerting your members, maximum people would be able to benefit from access to our top class scientific content.

If you require further assistance, please contact us at: hermain@benthamscience.net CC: faizan@benthamscience.net

 

 

Abstracts Ahead of Print | Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Author(s): Alessandra Bearz, Sara Cecco, Sara Francescon, Francesco Lo Re, Giuseppe Corona, Paolo Baldo*.

 

 

imgpsh_fullsize_anim.png

 

Background: Lung cancer is the most frequent cause of cancer-related death. In the last decades, the introduction of targeted therapies and more recently, of immunotherapy, has led to significant improvements in different outcomes of this malignant neoplasm.

Objective: The present review provides a balanced overview of most recent targeted therapies and immunotherapies patented for the treatment of lung cancer.

Method: An extensive scientific literature and patent databases search were performed to identify peer-reviewed studies containing information on recently patented drugs for the treatment of lung cancer, with a particular focus on their safety data and recently patented combinations.

Results: The development of therapies directed to different pathways involved in the tumor angiogenesis, proliferation, and metastasis has transformed the clinical practice of lung malignancies. Several clinical trials have shown an improvement in terms of progression-free survival and overall survival in patients with advanced/metastatic lung cancer. Safety data, extracted from clinical trials and from the WHO global database of adverse drug reactions (VigiAccessTM database), show that recently patented drugs for the treatment of lung cancer are well- tolerated and most of the adverse events reported are mild to moderate.

Conclusion: Currently, a consistent number of new drugs and combinations have been introduced for the treatment of patients with advanced-stage lung cancer. Safety data remain essential to better assess the long-term risk/benefit ratio of these valuable emerging therapies. The new patents’ development could provide further significant improvements for lung cancer treatment. To read full abstract, please visit: http://www.eurekaselect.com/173895/article

Abstracts Ahead of Print | Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma

Author(s): Debora Basile, Camilla Lisanti, Maria A. Pizzichetta, Paolo Baldo*, Giulia Fornasier, Francesco Lo Re, Giuseppe Corona, Fabio Puglisi.

 

imgpsh_fullsize_anim (2).png

 

Background: Malignant melanoma is a skin cancer responsible of 90% of cutaneous cancer related deaths. In recent years, breakthroughs in treatment strategy have revolutionized the prognosis both of early and advanced melanoma patients. In particular, treatment with monoclonal antibodies targeting co-inhibitory checkpoints or specific molecular pathways are pawing the way for a new era of promising options, by prolonging survival time of these patients.

Moreover, unlike the chemotherapy that was used until some time ago, these new drugs have a good and more manageable toxicity profile. However, because of the recent introduction in clinical practice of the new agents, there is a learning curve among physicians regarding early recognition and management of the associated side effects.

Objectives: The analysis of the toxicity profiles of the different agents currently studied for the treatment of early and advanced melanoma, and the description of several relevant recent patents in this field, are the aims of this review.

Methods: A systematically conducted review, based on current clinical guidelines and on international Pharmacovigilance databases (AERS-Eudravigilance – WHO Vigibase).

Results: Our systematic analysis outlines a comprehensive overview about the pharmacology, clinical application and safety of recent anticancer drugs to treat melanoma, which can be an essential instrument for health professionals and researchers.

Conclusion: The new oncological therapies against melanoma are based on increasingly specific biological and immunological targets. For this reason, the potential toxicities that are expected from patients would be less relevant than the systemic “classical” chemotherapy. However, the new therapies are not free from the risk of causing adverse reactions, some of which must be managed promptly and appropriately; moreover the multiplicity of the metabolic pathways exposes the new target therapies to relevant potential interactions. This review can help to understand how important it is not to underestimate potential adverse drug reactions related to new targeted therapies. To read the full abstract, please visit: http://www.eurekaselect.com/173896/article

Abstracts Ahead of Print | Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Author(s): Emanuela Vaccher, Ornella Schioppa, Ferdinando Martellotta, Giulia Fornasier, Elisa Giacomin, Francesco Lo Re, Paolo Baldo*, Giuseppe Corona, Carlo Gobitti.

 

imgpsh_fullsize_anim (1).png

Background: Thyroid cancer is the most common endocrine neoplasia and represents approximately 1.5% to 2.1% of all cancers diagnosed annually worldwide. Iodine refractory differentiated thyroid carcinoma (RR-DTC) and advanced/metastatic medullary thyroid carcinoma are relatively uncommon yet prognostically significant thyroid cancers. Gene rearrangements resulting in the aberrant activity of tyrosine kinases have been identified as drivers of oncogenesis in a variety of cancers, including thyroid cancer. Many Multi-Kinase Inhibitors (MKIs) which are now FDA-/EMA-approved for thyroid cancer have shown clinical benefit in patients with advanced cancer. Treatment-related toxicities occur frequently with these drugs and can be severe or life-threatening.

Objectives: This review summarizes the role of targeted therapy with MKIs in the management of RR-DTC and advanced/metastatic MTC patients, focusing on side-effect profiles of these drugs, with a presentation of several recent patents published in this field.

Methods: We review the scientific literature about advanced thyroid cancer and we analyze the International Pharmacovigilance database (FAERS, Eudravigilance, and WHO Vigibase) for adverse drug reactions.

Results: This systematic analysis highlights the difference of the safety profile between the recent drugs used in the treatment of advanced thyroid cancer and the recent patient discovered to diagnose or to treat the thyroid cancer.

Conclusion: It is essential to investigate the safety profile of the recent anticancer drugs for advanced thyroid cancer to allow health professionals to make the best choice for each patient by evaluating the risk/benefit assessment. To read the full asbtract, please visit: http://www.eurekaselect.com/173897/article

Publish your medical research for free | Current Dentistry

Publish your Medical Research for FREE in our journal CURRENT DENTISTRY

All articles published in the first year would be free!

 

Current Dentistry.jpg

 

AIMS & SCOPE

Current Dentistry , a peer-reviewed journal, publishes original research, full-length/mini reviews, and thematic issues in all areas of dental, oral and craniofacial sciences including biological, clinical, materials engineering and bio engineering aspects of dental research. The journal will be of interest to researchers in dental, oral, hard-tissue, and craniofacial science. To know more about the journal, please visit: https://benthamscience.com/journals/current-dentistry/

 

To submit your paper, email at: hermain@benthamscience.net and CC: faizan@benthamscience.net

 

 

 

%d bloggers like this: